Recent acquisitions and strong sales for vaccines and rare disease medicines lifted Sanofi SA in the first quarter after a lacklustre performance in 2018. The French company reported net sales of €8.4 billion for the quarter, up by 6.2% from a year earlier and net income of €1.14 billion, up by 11.9%. This followed a restructuring of its portfolio to focus on specialty medicines and away from insulins. With an operating profit of €1.4 billion, the company delivered an operating margin of 17%.
